NovoCodex Biopharmaceuticals focuses on the research and development of biopharmaceutical products, emphasizing innovative technologies to meet clinical needs. The company has established a comprehensive biopharmaceutical laboratory equipped with capabilities in various areas, including gene engineering, cell culture, toxin synthesis, antibody-drug conjugation (ADC), formulation filling, and both preclinical and clinical research. This extensive expertise allows NovoCodex to develop advanced therapeutic solutions, particularly in the field of oncology.

One of the notable projects under development is the AS269 antibody-drug conjugate, which targets HER2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma. The company is conducting international multicenter clinical studies to evaluate the efficacy and safety of this innovative treatment. With a production capacity of 600,000 bottles per year for the AS269 conjugate, NovoCodex is positioned to contribute significantly to the biopharmaceutical landscape, particularly in the development of targeted cancer therapies.

China

Developer of biotechnology focused on biopharmaceuticals. The company's innovative biologic drug anti-HER2 is a new generation of monoclonal.

NovoCodex Biopharmaceuticals

Company Details